ArticleJACC. Case reports2025
Anti-VEGF Therapy-Induced Accelerated Atherosclerosis: STEMI in a Young Adult.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting lymphatic dysfunction in atherosclerosis: a state-of-the-art review on potential therapies and future directions.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBevacizumab is an antiangiogenic monoclonal antibody used in several primary and secondary central nervous system malignancies to reduce refractory cerebral edema. However, long-term therapy may lead to accelerated atherosclerosis through endothelial dysfunction and proteinuria-driven hyperlipidemia. CASE SUMMARY: A 27-year-old man with neurofibromatosis type 2 on long-term bevacizumab presented with progressively worsening chest pain and subsequently experienced ventricular fibrillation arrest. Emergent angiography identified an anomalous right coronary artery occlusion causing an inferior ST-segment elevation myocardial infarction and demonstrated left coronary atherosclerotic disease. He underwent successful percutaneous coronary intervention and guideline-based therapy for heart failure with reduced ejection fraction. Bevacizumab-induced endothelial injury and hyperlipidemia were implicated in premature coronary artery disease. DISCUSSION: This case underscores the interplay between inhibition of angiogenesis and early coronary atherosclerosis, highlighting the importance of nitric oxide derangement and proteinuria-induced dyslipidemia. Clinicians must remain vigilant about cardiovascular complications in young patients on long-term bevacizumab. TAKE-HOME MESSAGE: Bevacizumab may accelerate atherosclerosis; early detection and risk factor reduction including lipid control and tight blood pressure management are crucial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.